Kolfarma was founded in 2009 following studies and research carried out at the University of Genoa, focusing on the potential anti-epileptic effect of a whey protein, alpha-lactalbumin (ALAC) .

Clinical studies on patients with epilepsy treated with selective serotonin reuptake inhibitor (SSRI) antidepressants led to the search for a new way to increase serotonin synthesis in the central nervous system (CNS). Alpha-lactalbumin was identified as having this effect.

Subsequent research highlights the role of the intestinal microbiota in the morbidity of various pathologies.

In particular, Kolfarma is committed to promoting projects to understand how modulating the microbiota can influence the functioning of other organs, with a primary interest in the brain and the Central Nervous System.

Kolfarma is constantly committed to the dissemination of new scientific knowledge , also through sponsorship of activities such as conferences, congresses, workshops, webinars and educational campaigns.

Kolfarma is proud to continue funding preclinical and clinical studies to better understand the role of the microbiota in the control of epileptic seizures and in the management of various neuropsychiatric disorders and their comorbidities, particularly in the pediatric area.

Kolfarma owns 3 international patents , demonstrating the quality and seriousness of the research carried out and the products marketed, in Italy and also internationally.